A ferroptosis-inducing biomimetic nanocomposite for the treatment of drug-resistant prostate cancer

Second-generation androgen receptor (AR) inhibitors such as enzalutamide are the first-line treatments for castration-resistant prostate cancer (CRPC). Resistance to enzalutamide will greatly increase the difficulty of prostate cancer treatment and reduce the survival time of patients. However, drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiyuan, Wang, Yujie, Han, Lu, Wang, Rong, Gong, Chunai, Yang, Gang, Li, Zhe, Gao, Shen, Yuan, Yongfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649379/
https://www.ncbi.nlm.nih.gov/pubmed/36388460
http://dx.doi.org/10.1016/j.mtbio.2022.100484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649379/
https://www.ncbi.nlm.nih.gov/pubmed/36388460
http://dx.doi.org/10.1016/j.mtbio.2022.100484

Ejemplares similares